{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-273808","form_type":"8-K","ticker":"ATRA","cik":"0001604464","company_name":"Atara Biotherapeutics, Inc.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.745413+00:00","generated_at":"2026-06-08T06:43:30.572433+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Atara's Phase 2 ATA188 for non-active PMS misses primary endpoint; cash runway extended beyond Q3 2025","bullets":["EMBOLD misses primary endpoint; treatment arm CDI 6% vs 33% in Phase 1; placebo rate 16% exceeded expected 4-6%.","No new safety signals observed; favorable safety profile for ATA188 in the study.","Company plans significant expense reductions on ATA188; focuses on allogeneic CAR-T pipeline; cash runway extended beyond Q3 2025.","Catalysts: ATA3431 preclinical data at ASH Dec 2023; Phase 1 data for ATA3219 in B-NHL expected H2 2024.","Tab-cel partnership with Pierre Fabre provides additional payments and significant double-digit royalties."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-273808","json":"https://secwatch.observer/filing/0001193125-23-273808.json","markdown":"https://secwatch.observer/filing/0001193125-23-273808.md","text":"https://secwatch.observer/filing/0001193125-23-273808.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1604464/000119312523273808/0001193125-23-273808-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1604464/000119312523273808/d139069d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T06:43:30.572433+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}